WO2020139866A3 - Compositions and methods for treating cancer - Google Patents
Compositions and methods for treating cancer Download PDFInfo
- Publication number
- WO2020139866A3 WO2020139866A3 PCT/US2019/068423 US2019068423W WO2020139866A3 WO 2020139866 A3 WO2020139866 A3 WO 2020139866A3 US 2019068423 W US2019068423 W US 2019068423W WO 2020139866 A3 WO2020139866 A3 WO 2020139866A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dsrna
- sense strand
- antisense strand
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19904756.4A EP3902917A4 (en) | 2018-12-27 | 2019-12-23 | Compositions and methods for treating cancer |
CA3163139A CA3163139A1 (en) | 2018-12-27 | 2019-12-23 | Compositions and methods for treating cancer |
CN201980093039.3A CN113508175A (en) | 2018-12-27 | 2019-12-23 | Compositions and methods for treating cancer |
US17/359,905 US20230035774A1 (en) | 2018-12-27 | 2021-06-28 | Compositions and Methods for Treating Cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785592P | 2018-12-27 | 2018-12-27 | |
US62/785,592 | 2018-12-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/359,905 Continuation-In-Part US20230035774A1 (en) | 2018-12-27 | 2021-06-28 | Compositions and Methods for Treating Cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020139866A2 WO2020139866A2 (en) | 2020-07-02 |
WO2020139866A3 true WO2020139866A3 (en) | 2020-10-15 |
Family
ID=71129313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/068423 WO2020139866A2 (en) | 2018-12-27 | 2019-12-23 | Compositions and methods for treating cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3902917A4 (en) |
CN (1) | CN113508175A (en) |
CA (1) | CA3163139A1 (en) |
WO (1) | WO2020139866A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4363577A1 (en) * | 2021-06-28 | 2024-05-08 | bioAffinity Technologies, Inc. | Compositions and methods for treating cancer |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239270B1 (en) * | 1993-05-24 | 2001-05-29 | Rhone-Poulenc Rorer S.A. | Nucleic acids encoding human calcium sensor protein |
US20030004311A1 (en) * | 1997-06-18 | 2003-01-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20060234260A1 (en) * | 1997-11-28 | 2006-10-19 | Serono Genetics Institute S.A. | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
WO2007140506A1 (en) * | 2006-06-02 | 2007-12-13 | Human Genetic Signatures Pty Ltd | Modified microbial nucleic acid for use in detection and analysis of microorganisms |
US20080050393A1 (en) * | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
WO2008116171A1 (en) * | 2007-03-21 | 2008-09-25 | Raptor Pharmaceutical Inc. | Cyclic receptor-associated protein (rap) peptides |
US20110195523A1 (en) * | 2006-03-28 | 2011-08-11 | Niigata University | Method for measuring human megalin |
US20140068793A1 (en) * | 2006-04-07 | 2014-03-06 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
WO2017223273A1 (en) * | 2016-06-22 | 2017-12-28 | President And Fellows Of Harvard College | Inhibition of colonic group 3 innate lymphoid cells |
US10113201B2 (en) * | 2013-04-05 | 2018-10-30 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of glioblastoma or a subtype thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053455A2 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2007117657A2 (en) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US11788145B2 (en) * | 2015-07-17 | 2023-10-17 | Pacylex Pharmaceuticals Inc. | Epigeneiic silencing of NMT2 |
-
2019
- 2019-12-23 CA CA3163139A patent/CA3163139A1/en active Pending
- 2019-12-23 EP EP19904756.4A patent/EP3902917A4/en active Pending
- 2019-12-23 WO PCT/US2019/068423 patent/WO2020139866A2/en unknown
- 2019-12-23 CN CN201980093039.3A patent/CN113508175A/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239270B1 (en) * | 1993-05-24 | 2001-05-29 | Rhone-Poulenc Rorer S.A. | Nucleic acids encoding human calcium sensor protein |
US20030004311A1 (en) * | 1997-06-18 | 2003-01-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20060234260A1 (en) * | 1997-11-28 | 2006-10-19 | Serono Genetics Institute S.A. | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
US20080050393A1 (en) * | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
US20110195523A1 (en) * | 2006-03-28 | 2011-08-11 | Niigata University | Method for measuring human megalin |
US20140068793A1 (en) * | 2006-04-07 | 2014-03-06 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US9044461B2 (en) * | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
WO2007140506A1 (en) * | 2006-06-02 | 2007-12-13 | Human Genetic Signatures Pty Ltd | Modified microbial nucleic acid for use in detection and analysis of microorganisms |
WO2008116171A1 (en) * | 2007-03-21 | 2008-09-25 | Raptor Pharmaceutical Inc. | Cyclic receptor-associated protein (rap) peptides |
US10113201B2 (en) * | 2013-04-05 | 2018-10-30 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of glioblastoma or a subtype thereof |
WO2017223273A1 (en) * | 2016-06-22 | 2017-12-28 | President And Fellows Of Harvard College | Inhibition of colonic group 3 innate lymphoid cells |
Non-Patent Citations (3)
Title |
---|
DATABASE GENBANK [online] 26 December 2017 (2017-12-26), "PREDICTED: Seriola lalandi dorsalis pleckstrin -homology and RhoGEF domain containing G3 (plekhg3), mRNA; Publication", Database accession no. XM 023408803.1 * |
LEARY, M ET AL.: "Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy", CANCERS, vol. 10, no. 483, 4 December 2018 (2018-12-04), pages 1 - 18, XP055747657 * |
SILVIA MONTEAGUDO, FRANCISCO C PÉREZ-MARTÍNEZ, MARÍA D PÉREZ-CARRIÓN, JAVIER GUERRA, SONIA MERINO, MARÍA PRADO SÁNCHEZ-VERDÚ , VAL: "Inhibition of p42 MAPK using a nonviral vector-delivered siRNA - potentiates the anti-tumor effect of meformin in prostate cancer cells", NANOMEDICINE, vol. 7, no. 4, 1 April 2012 (2012-04-01), pages 493 - 506, XP055824058, ISSN: 1743-1559, DOI: 10.2217/nnm.11.61 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020139866A2 (en) | 2020-07-02 |
EP3902917A4 (en) | 2022-11-30 |
CA3163139A1 (en) | 2020-07-02 |
CN113508175A (en) | 2021-10-15 |
EP3902917A2 (en) | 2021-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004083430A3 (en) | SHORT INTERFERING RNA (siRNA) ANALOGUES | |
PH12020500622A1 (en) | 17á-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
BR112016013148A2 (en) | "Complement component component compositions and methods of using them | |
WO2006128141A3 (en) | Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina) | |
WO2007134161A8 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
NZ602404A (en) | Compositions and methods for inhibiting expression of transthyretin | |
WO2008109450A3 (en) | Nucleic acid compounds for inhibiting id-1 gene expression and uses thereof | |
WO2007022369A8 (en) | Chemically modified short interfering nucleic acid molecules that mediate rna interference | |
WO2003070970A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) | |
WO2007084865A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2014022739A3 (en) | Modified rnai agents | |
WO2011008730A3 (en) | Chemical modification of small hairpin rnas for inhibition of gene expression | |
WO2007128477A3 (en) | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION | |
WO2008049078B1 (en) | Nicked or gapped nucleic acid molecules and uses thereof | |
WO2008008719A3 (en) | Compositions and methods for inhibiting expression of the myc gene | |
WO2007076328A3 (en) | Rna interference mediated inhibition of hepatitis c virus | |
WO2004092383A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2005045037A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2003070887A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2019014530A8 (en) | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof | |
WO2005007855A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2008109516A3 (en) | Nucleic acid compounds for inhibiting ras gene expression and uses thereof | |
WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene | |
WO2020139866A3 (en) | Compositions and methods for treating cancer | |
WO2011139843A3 (en) | Multi-sirna compositions for reducing gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19904756 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019904756 Country of ref document: EP Effective date: 20210727 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19904756 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3163139 Country of ref document: CA |